Difference between revisions of "Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection"

From OmniJournal
Jump to navigation Jump to search
(Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://onlinelibrary.wiley.com/doi/10.1002/j...")
 
 
Line 25: Line 25:
 
== Major Issues ==
 
== Major Issues ==
  
No major issues identified.  
+
No major issues identified at this time.  
  
 
== Minor Issues ==
 
== Minor Issues ==
  
No minor issues identified.
+
No minor issues identified at this time.
  
 
== Impact ==
 
== Impact ==

Latest revision as of 17:04, 22 July 2020

Publication
Title
Authors
  • A Ferreira, MD PhD
  • A Oliveira-e-Silva, MD
  • P Bettencourt, MD PhD
Journal Journal of Medical Virology
Date July 9, 2020

Retrospective analysis of patients with systemic lupus erythematosus, rheumatoid arthritis and other autoimmune disorders showed that patients receiving hydroxychloroquine had an odds ratio of COVID-19 of 0.51 (CI 0.37-0.70) compared to patients with autoimmune diseases who were receiving other therapeutics.

This analysis suggests a prophylactic effect of hydroxychloroquine against COVID-19.

Of note, hydroxychloroquine was not shown to be entirely protective against COVID-19 as 5.96% of patients receiving chronic treatment with hydroxychloroquine still became infected with novel-coronavirus compared to the 7.45% infection incidence in patients not receiving hydroxychloroquine.

Major Issues

No major issues identified at this time.

Minor Issues

No minor issues identified at this time.

Impact

This is another retrospective analysis that suggests a prophylactic effect of hydroxychloroquine against COVID-19.

Article Revisions

None at this time.

References